Results from the NorthStar trial highlight the potential for integrating local therapy with targeted agents to extend disease control in this setting
Study results support alternative treatment regimens in prostate and urothelial tumours, showing similar efficacy to standard care while reducing treatment burden
Follow-up data at 7 and 5 years from monarchE and NATALEE provide reassurance of the sustained benefits of adjuvant CDK4/6 inhibitors in improving survival and reducing relapse
While a HER2-targeted bispecific antibody showed extended survival in pre-treated gastric cancers, TKI–immunotherapy combinations failed to confer a survival benefit
An ESMO roadmap addresses how the new challenges in oncology can be transformed into opportunities for the benefits of oncology professionals and patients with cancer
Growing evidence shows that AI models can predict a patient's disease trajectory and signal the need for early therapeutic intervention
The 2025 ESMO Awardee, Thierry Conroy, traces the major advances in the field while noting that several barriers to improving patient outcomes remain
The 2025 ESMO Lifetime Achievement Awardee, Prof. Rolf Stahel, reflects on the role of the oncology community to drive progress in cancer care
Receiving the 2025 ESMO Women for Oncology Award, Dr Natasha Leighl stresses the importance of passing along learnings, support and opportunities to others
Glenda Ramos Martínez receives the ESMO Oncologist of the Year Award, launched this year by the Society
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.